CSL Limited (ASX: CSL)
Analysts at UBS have retained their buy rating and lifted the price target on this biotherapeutics company’s shares to $346.00. This follows an FY 2020 result which was in line with expectations and positive guidance for the year ahead. Overall, it appears to see a decent risk/reward on offer with its shares at the current level. I would have to agree with UBS on this one and believe CSL is a great option for investors.
UBS lifted the price target for CSL
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$299.63 |
Change
2.130(0.72%) |
Mkt cap ! $144.1B | |||
| Open | High | Low | Value | Volume |
| $297.75 | $299.80 | $297.02 | $82.26M | 281.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 68 | $299.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $299.64 | 7 | 2 |
View Market Depth
| Last trade - 13.18pm 05/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |